首页 > 最新文献

Klinicheskaia meditsina最新文献

英文 中文
Medical staff of the Russian Expeditionary Force and the Honorary Russian Legion in France 在法国的俄罗斯远征军和俄罗斯荣誉军团的医务人员
Pub Date : 2023-09-22 DOI: 10.30629/0023-2149-2023-101-7-8-416-424
V. B. Simonenko, V. G. Abashin, P. E. Krynyukov, P. A. Dulin
The data on the warfare of the Russian Expeditionary Force and the Honorary Russian Legion in France during the First World War are presented. A study of the biographical data of the military doctors of the Force was carried out, and their fates were traced in some cases. Information is given about the hospitals and infi rmaries of the Russian Red Cross Society, their work in France. The facts about the sisters of mercy of the RRCS are also provided.
介绍了第一次世界大战期间俄罗斯远征军和俄罗斯荣誉军团在法国的作战资料。对部队军医的履历资料进行了研究,在某些情况下追查了他们的命运。介绍了俄罗斯红十字会的医院和医务室及其在法国的工作。同时也提供了rcs慈悲修女会的事实。
{"title":"Medical staff of the Russian Expeditionary Force and the Honorary Russian Legion in France","authors":"V. B. Simonenko, V. G. Abashin, P. E. Krynyukov, P. A. Dulin","doi":"10.30629/0023-2149-2023-101-7-8-416-424","DOIUrl":"https://doi.org/10.30629/0023-2149-2023-101-7-8-416-424","url":null,"abstract":"The data on the warfare of the Russian Expeditionary Force and the Honorary Russian Legion in France during the First World War are presented. A study of the biographical data of the military doctors of the Force was carried out, and their fates were traced in some cases. Information is given about the hospitals and infi rmaries of the Russian Red Cross Society, their work in France. The facts about the sisters of mercy of the RRCS are also provided.","PeriodicalId":17856,"journal":{"name":"Klinicheskaia meditsina","volume":"71 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136098689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis and surgical treatment of congenital anomalies of the development of the female genital organs 女性生殖器官发育先天性异常的诊断与外科治疗
Pub Date : 2023-09-22 DOI: 10.30629/0023-2149-2023-101-7-8-410-412
A. E. Solovyev, L. F. Pritulo, E. F. Gerashenko, K. S. Toncheva
In the departments of pediatric surgery in clinics in Ryazan and Zaporizhia, 5 girls aged 12–16 years with malformations of the urinary and genital system were observed: duplication of the vagina and uterus, aplasia of the duplicated vagina in combination with aplasia of the kidney on the side of the malformation. In 3 children, the combined defect was right-sided, in 2 — left-sided, and accompanied by hematocolpos and hematometra. In the diagnosis of malformations of the urinary and genital system in girls, anamnesis, examination of the abdominal cavity and bimanual examination, ultrasound examination, excretory urography, vaginoscopy, and computed tomography were used. Currently, surgical excision of the underdeveloped vaginal wall is performed to empty it from menstrual discharge. The imposition of a wide window in the septum between the aplastic and healthy vagina is the preferred operation. Further observations are carried out by gynecologists.
在梁赞和扎波罗热的儿科外科,观察了5例12-16岁的泌尿和生殖系统畸形的女孩:阴道和子宫的复制,复制的阴道发育不全并畸形一侧的肾脏发育不全。3例患儿合并畸形为右侧,2例为左侧,并伴有积血和积血。在诊断女童泌尿生殖系统畸形时,主要采用健忘症、腹腔检查和双手检查、超声检查、排泄尿路造影、阴道镜检查和计算机断层扫描。目前,外科手术切除不发达的阴道壁,使其排出月经分泌物。在可再生阴道和健康阴道之间的隔膜上开一个宽窗是首选的手术。进一步的观察由妇科医生进行。
{"title":"Diagnosis and surgical treatment of congenital anomalies of the development of the female genital organs","authors":"A. E. Solovyev, L. F. Pritulo, E. F. Gerashenko, K. S. Toncheva","doi":"10.30629/0023-2149-2023-101-7-8-410-412","DOIUrl":"https://doi.org/10.30629/0023-2149-2023-101-7-8-410-412","url":null,"abstract":"In the departments of pediatric surgery in clinics in Ryazan and Zaporizhia, 5 girls aged 12–16 years with malformations of the urinary and genital system were observed: duplication of the vagina and uterus, aplasia of the duplicated vagina in combination with aplasia of the kidney on the side of the malformation. In 3 children, the combined defect was right-sided, in 2 — left-sided, and accompanied by hematocolpos and hematometra. In the diagnosis of malformations of the urinary and genital system in girls, anamnesis, examination of the abdominal cavity and bimanual examination, ultrasound examination, excretory urography, vaginoscopy, and computed tomography were used. Currently, surgical excision of the underdeveloped vaginal wall is performed to empty it from menstrual discharge. The imposition of a wide window in the septum between the aplastic and healthy vagina is the preferred operation. Further observations are carried out by gynecologists.","PeriodicalId":17856,"journal":{"name":"Klinicheskaia meditsina","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136099293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of patients with chronic thromboembolic pulmonary hypertension 慢性血栓栓塞性肺动脉高压患者的治疗
Pub Date : 2023-09-22 DOI: 10.30629/0023-2149-2023-101-7-8-361-367
O. Ya. Vasiltseva, A. E. Uranov, A. G. Edemskiy, E. N. Kliver, D. S. Grankin, D. A. Sirota, A. B. Romanov, A. M. Chernyavskiy
The understanding of the tactics for managing patients with pulmonary hypertension (PH) of various etiologies is currently being developed. In August 2022, the European Society of Cardiology adopted new Guidelines for the management of patients with pulmonary hypertension. A separate cohort among them consists of patients with chronic thromboembolic pulmonary hypertension (CTEPH), classifi ed as Group 4 according to the WHO classifi cation. The possibilities of diagnosis, treatment methods, and their availability for this pathology have signifi cantly expanded over the past two decades. The aim of this study is to familiarize physicians with modern methods of treating CTEPH in order to timely refer patients to the most eff ective types of treatment currently available in expert centers in the Russian Federation. Materials and methods . The strategy for searching sources involved analyzing Medline (PubMed) and Scopus databases for the past 20 years using keywords such as diagnostic criteria for chronic thromboembolic pulmonary hypertension, treatment of chronic thromboembolic pulmonary hypertension. To search for additional materials on the topic, the lists of literature in relevant articles and reviews were analyzed.
对各种病因的肺动脉高压(PH)患者的治疗策略的理解目前正在发展。2022年8月,欧洲心脏病学会通过了新的肺动脉高压患者管理指南。其中一个单独的队列由慢性血栓栓塞性肺动脉高压(CTEPH)患者组成,根据世卫组织分类为第4组。在过去的二十年中,这种病理的诊断、治疗方法及其可用性的可能性已经显著扩大。本研究的目的是使医生熟悉治疗CTEPH的现代方法,以便及时将患者转介到俄罗斯联邦专家中心目前可用的最有效的治疗类型。材料和方法。搜索来源的策略包括分析Medline (PubMed)和Scopus数据库过去20年的检索结果,关键词包括慢性血栓栓塞性肺动脉高压的诊断标准、慢性血栓栓塞性肺动脉高压的治疗。为了寻找关于该主题的其他资料,我们分析了相关文章和综述中的文献列表。
{"title":"Treatment of patients with chronic thromboembolic pulmonary hypertension","authors":"O. Ya. Vasiltseva, A. E. Uranov, A. G. Edemskiy, E. N. Kliver, D. S. Grankin, D. A. Sirota, A. B. Romanov, A. M. Chernyavskiy","doi":"10.30629/0023-2149-2023-101-7-8-361-367","DOIUrl":"https://doi.org/10.30629/0023-2149-2023-101-7-8-361-367","url":null,"abstract":"The understanding of the tactics for managing patients with pulmonary hypertension (PH) of various etiologies is currently being developed. In August 2022, the European Society of Cardiology adopted new Guidelines for the management of patients with pulmonary hypertension. A separate cohort among them consists of patients with chronic thromboembolic pulmonary hypertension (CTEPH), classifi ed as Group 4 according to the WHO classifi cation. The possibilities of diagnosis, treatment methods, and their availability for this pathology have signifi cantly expanded over the past two decades. The aim of this study is to familiarize physicians with modern methods of treating CTEPH in order to timely refer patients to the most eff ective types of treatment currently available in expert centers in the Russian Federation. Materials and methods . The strategy for searching sources involved analyzing Medline (PubMed) and Scopus databases for the past 20 years using keywords such as diagnostic criteria for chronic thromboembolic pulmonary hypertension, treatment of chronic thromboembolic pulmonary hypertension. To search for additional materials on the topic, the lists of literature in relevant articles and reviews were analyzed.","PeriodicalId":17856,"journal":{"name":"Klinicheskaia meditsina","volume":"62 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136098846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epigenetic signals in heart failure: new opportunities for early diagnosis and eff ective therapy 心力衰竭的表观遗传信号:早期诊断和有效治疗的新机会
Pub Date : 2023-09-22 DOI: 10.30629/0023-2149-2023-101-7-8-353-360
K. A. Aitbaev, I. T. Murkamilov, V. V. Fomin, I. O. Kudaibergenova, F. A. Yusupov, Z. A. Aidarov
Heart failure (HF) is a severe clinical syndrome associated with signifi cant morbidity and mortality. According to the mechanisms of HF development, it is divided into two main clinical forms: heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). While eff ective and specifi c treatment methods have been developed for HFrEF, leading to a decrease in the prevalence of this form of HF in recent years, the prognosis for patients with HFpEF remains unfavourable, and eff ective treatment methods do not yet exist. Therefore, the identifi cation of new molecular targets and therapeutic approaches is considered an important task of modern medicine. Data obtained in this fi eld have revealed the key involvement of epigenetic signals in the regulation of transcriptional programs underlying the development of HFpEF, which has contributed to the development of selective epigenetic drugs capable of reversing transcriptional changes and thus delaying or preventing the progression of HFpEF. Further thorough investigation of individual epigenetic landscapes may provide opportunities in the future for the development of personalized epigenetic biomarkers and treatment methods for HFpEF. The aim of this review is to consider the role of epigenetic processing, as well as its diagnostic and therapeutic possibilities in HFpEF.
心力衰竭(HF)是一种严重的临床综合征,具有很高的发病率和死亡率。根据HF的发生机制,临床主要分为两种形式:心力衰竭伴射血分数降低(HFrEF)和心力衰竭伴射血分数保留(HFpEF)。虽然已经开发出有效和特异性的治疗方法,导致近年来这种HF的患病率有所下降,但HFpEF患者的预后仍然不利,目前还没有有效的治疗方法。因此,寻找新的分子靶点和治疗途径被认为是现代医学的重要任务。该领域获得的数据揭示了表观遗传信号在HFpEF发展的转录程序调控中的关键作用,这有助于开发能够逆转转录变化的选择性表观遗传药物,从而延缓或阻止HFpEF的进展。进一步深入研究个体表观遗传景观可能为HFpEF的个性化表观遗传生物标志物和治疗方法的开发提供机会。这篇综述的目的是考虑表观遗传加工的作用,以及它在HFpEF的诊断和治疗的可能性。
{"title":"Epigenetic signals in heart failure: new opportunities for early diagnosis and eff ective therapy","authors":"K. A. Aitbaev, I. T. Murkamilov, V. V. Fomin, I. O. Kudaibergenova, F. A. Yusupov, Z. A. Aidarov","doi":"10.30629/0023-2149-2023-101-7-8-353-360","DOIUrl":"https://doi.org/10.30629/0023-2149-2023-101-7-8-353-360","url":null,"abstract":"Heart failure (HF) is a severe clinical syndrome associated with signifi cant morbidity and mortality. According to the mechanisms of HF development, it is divided into two main clinical forms: heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). While eff ective and specifi c treatment methods have been developed for HFrEF, leading to a decrease in the prevalence of this form of HF in recent years, the prognosis for patients with HFpEF remains unfavourable, and eff ective treatment methods do not yet exist. Therefore, the identifi cation of new molecular targets and therapeutic approaches is considered an important task of modern medicine. Data obtained in this fi eld have revealed the key involvement of epigenetic signals in the regulation of transcriptional programs underlying the development of HFpEF, which has contributed to the development of selective epigenetic drugs capable of reversing transcriptional changes and thus delaying or preventing the progression of HFpEF. Further thorough investigation of individual epigenetic landscapes may provide opportunities in the future for the development of personalized epigenetic biomarkers and treatment methods for HFpEF. The aim of this review is to consider the role of epigenetic processing, as well as its diagnostic and therapeutic possibilities in HFpEF.","PeriodicalId":17856,"journal":{"name":"Klinicheskaia meditsina","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136098851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality of life in patients after treatment of deep vein thrombosis with regional catheter thrombolysis 局部导管溶栓治疗深静脉血栓患者的生活质量
Pub Date : 2023-09-22 DOI: 10.30629/0023-2149-2023-101-7-8-376-380
B. S. Sukovatykh, A. V. Sereditsky, A. Yu. Grigoryan, M. B. Sukovatykh, V. M. Pashkov
The aim of the study was to compare the quality of life in patients after treatment of deep vein thrombosis with regional catheter thrombolysis using alteplase and urokinase, and to compare the results with clinical examination data. Material and methods. The assessment of quality of life and data from a control objective examination were conducted in 32 patients with deep vein thrombosis, divided into two statistically homogeneous groups of 16 individuals each. Alteplase was used for thrombolysis in the fi rst group, while urokinase was used in the second group. The quality of life in patients was evaluated using two questionnaires: SF-36 and CIVIQ-20. The severity of venous disease was determined based on the clinical assessment of venous return impairment. Results . In the fi rst group, the physical component of health according to the SF-36 questionnaire was 56 (49.5; 56.3), the psychological component was 54 (50; 68.8), while in the second group it was 34 (33; 34) and 38 (31.3; 45) respectively. The overall health assessment according to the CIVIQ-20 questionnaire was 20 (10.8; 30) in the fi rst group and 40 (32.8; 43.8) in the second group. In the clinical examination, venous return impairment was absent or mild in 75% of patients in the fi rst group, and equally distributed between mild and severe in 50% of patients in the second group. Conclusion . Alteplase thrombolysis has a more positive impact on the quality of life in patients compared to urokinase.
本研究的目的是比较阿替普酶和尿激酶局部导管溶栓治疗深静脉血栓患者的生活质量,并将结果与临床检查数据进行比较。材料和方法。对32例深静脉血栓患者进行生活质量评价和对照客观检查,分为两组,每组16例。第一组采用阿替普酶溶栓,第二组采用尿激酶溶栓。采用SF-36和CIVIQ-20两份问卷对患者的生活质量进行评估。根据静脉回流损害的临床评估来判断静脉疾病的严重程度。结果。第一组受试者根据SF-36问卷,身体健康成分为56分(49.5分;56.3),心理成分为54 (50;68.8),而第二组为34 (33;34)和38 (31.3;分别为45)。根据CIVIQ-20量表进行的总体健康评价为20分(10.8分;30例,40例(32.8例;43.8)为第二组。在临床检查中,第一组75%的患者无静脉回流障碍或轻度静脉回流障碍,第二组50%的患者轻度与重度静脉回流障碍平均分布。结论。与尿激酶相比,阿替普酶溶栓对患者的生活质量有更积极的影响。
{"title":"Quality of life in patients after treatment of deep vein thrombosis with regional catheter thrombolysis","authors":"B. S. Sukovatykh, A. V. Sereditsky, A. Yu. Grigoryan, M. B. Sukovatykh, V. M. Pashkov","doi":"10.30629/0023-2149-2023-101-7-8-376-380","DOIUrl":"https://doi.org/10.30629/0023-2149-2023-101-7-8-376-380","url":null,"abstract":"The aim of the study was to compare the quality of life in patients after treatment of deep vein thrombosis with regional catheter thrombolysis using alteplase and urokinase, and to compare the results with clinical examination data. Material and methods. The assessment of quality of life and data from a control objective examination were conducted in 32 patients with deep vein thrombosis, divided into two statistically homogeneous groups of 16 individuals each. Alteplase was used for thrombolysis in the fi rst group, while urokinase was used in the second group. The quality of life in patients was evaluated using two questionnaires: SF-36 and CIVIQ-20. The severity of venous disease was determined based on the clinical assessment of venous return impairment. Results . In the fi rst group, the physical component of health according to the SF-36 questionnaire was 56 (49.5; 56.3), the psychological component was 54 (50; 68.8), while in the second group it was 34 (33; 34) and 38 (31.3; 45) respectively. The overall health assessment according to the CIVIQ-20 questionnaire was 20 (10.8; 30) in the fi rst group and 40 (32.8; 43.8) in the second group. In the clinical examination, venous return impairment was absent or mild in 75% of patients in the fi rst group, and equally distributed between mild and severe in 50% of patients in the second group. Conclusion . Alteplase thrombolysis has a more positive impact on the quality of life in patients compared to urokinase.","PeriodicalId":17856,"journal":{"name":"Klinicheskaia meditsina","volume":"118 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136099294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Dermatopathic lymphadenopathy]. [Dermatopathic淋巴结病)。
Pub Date : 2020-02-08 DOI: 10.32388/yw3grw
A. Raben, N. Pokrovskaia, M. A. Reĭzinger, E. N. Unukova
{"title":"[Dermatopathic lymphadenopathy].","authors":"A. Raben, N. Pokrovskaia, M. A. Reĭzinger, E. N. Unukova","doi":"10.32388/yw3grw","DOIUrl":"https://doi.org/10.32388/yw3grw","url":null,"abstract":"","PeriodicalId":17856,"journal":{"name":"Klinicheskaia meditsina","volume":"142 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78516495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
[Reiter syndrome].
Pub Date : 2020-02-07 DOI: 10.32388/xzhejo
P. I. Korzhukova
{"title":"[Reiter syndrome].","authors":"P. I. Korzhukova","doi":"10.32388/xzhejo","DOIUrl":"https://doi.org/10.32388/xzhejo","url":null,"abstract":"","PeriodicalId":17856,"journal":{"name":"Klinicheskaia meditsina","volume":"38 1","pages":"103-5"},"PeriodicalIF":0.0,"publicationDate":"2020-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75730141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Primary hyperparathyroidism]. 原发性甲状旁腺功能亢进。
Pub Date : 2020-02-07 DOI: 10.32388/j2faj0
A. Kalinin, M. Balabolkin, V. S. Luk'ianchikov, D. N. Nurmanbetov
Current views on etiology, pathomorphology and pathophysiology of primary hyperparathyroidism are briefly outlined. In the last two decades the incidence of the disease has been on the increase. Clinical and diagnostic aspects, differential diagnosis of various pathogenetic forms of hypercalcemia are discussed. Basic problems of surgical treatment are considered. A scheme of hypercalcemia crisis management has been developed.
本文就原发性甲状旁腺功能亢进的病因、病理形态学和病理生理学的研究现状作一概述。在过去的二十年中,这种疾病的发病率一直在上升。临床和诊断方面,鉴别诊断的各种病因形式的高钙血症进行了讨论。讨论了手术治疗的基本问题。制定了高钙血症危机管理方案。
{"title":"[Primary hyperparathyroidism].","authors":"A. Kalinin, M. Balabolkin, V. S. Luk'ianchikov, D. N. Nurmanbetov","doi":"10.32388/j2faj0","DOIUrl":"https://doi.org/10.32388/j2faj0","url":null,"abstract":"Current views on etiology, pathomorphology and pathophysiology of primary hyperparathyroidism are briefly outlined. In the last two decades the incidence of the disease has been on the increase. Clinical and diagnostic aspects, differential diagnosis of various pathogenetic forms of hypercalcemia are discussed. Basic problems of surgical treatment are considered. A scheme of hypercalcemia crisis management has been developed.","PeriodicalId":17856,"journal":{"name":"Klinicheskaia meditsina","volume":"24 1","pages":"130-6"},"PeriodicalIF":0.0,"publicationDate":"2020-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80781915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Hemorrhagic gastritis]. 出血性胃炎。
Pub Date : 2020-02-07 DOI: 10.32388/2m3tw9
Ts G Masevich, B. A. Ziuss
{"title":"[Hemorrhagic gastritis].","authors":"Ts G Masevich, B. A. Ziuss","doi":"10.32388/2m3tw9","DOIUrl":"https://doi.org/10.32388/2m3tw9","url":null,"abstract":"","PeriodicalId":17856,"journal":{"name":"Klinicheskaia meditsina","volume":"18 1","pages":"56-60"},"PeriodicalIF":0.0,"publicationDate":"2020-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87308801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Prevention and treatment of obesity]. [肥胖的预防和治疗]。
Pub Date : 2018-10-01 DOI: 10.1542/9781610021395-part06-prevention
E. A. Beiul, V. Oleneva
{"title":"[Prevention and treatment of obesity].","authors":"E. A. Beiul, V. Oleneva","doi":"10.1542/9781610021395-part06-prevention","DOIUrl":"https://doi.org/10.1542/9781610021395-part06-prevention","url":null,"abstract":"","PeriodicalId":17856,"journal":{"name":"Klinicheskaia meditsina","volume":"57 1","pages":"128-32"},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76542536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Klinicheskaia meditsina
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1